Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-22T21:43:48.012Z Has data issue: false hasContentIssue false
  • English
  • Français

Pilot study of milnacipran in panic disorder

Published online by Cambridge University Press:  16 April 2020

M Ansseau ,
R von Frenckell  and
C Serre
M Ansseau
Affiliation:
Psychiatric Unit, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman (B35), B-4000 Liège 1, Belgium
R von Frenckell
Affiliation:
Psychiatric Unit, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman (B35), B-4000 Liège 1, Belgium
C Serre
Affiliation:
Centre de Recherche Pierre-Fabre, F-81106, Castres, France
Get access

Summary

Ten outpatients with panic disorder were treated over an 8 week-period with milnacipran, an antidepressant active on both noradrenergic and serotonergic systems, at a dose between 100 and 150 mg/d. Clinical assessments included the Hamilton Anxiety Scale and the Cottraux Rating Scale for phobias, panic attacks, and generalized anxiety. Results showed very significant improvements in the frequency and intensity of panic attacks and in the level of generalized anxiety. A good or excellent response was noted in 7 patients. Only 3 patients complained of side-effects, mostly of the digestive type. These promising results of milnacipran in panic disorder need to be confirmed in controlled studies.

Keywords

milnacipranpanic disorder
Type
Short communication
Information
European Psychiatry , Volume 6 , Issue 2 , 1991 , pp. 103 - 105
Copyright
Copyright © Elsevier, Paris 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1987) DSM III-R: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. American Psychiatric Association, Washington DCGoogle Scholar
Ansseau, Mvon Frenckell, RMertens, CDe Wilde, JBotte, LDevoitille, JMEvrard, JLDe Nayer, ADarimont, PDejaiffe, GMirel, JMeurice, EParent, MCouzinier, JPDemarez, JPSerre, C (1989a) Controlled comparison of two doses of milnacipran (F2207) and amitriptyline in major depressive inpatients. Psychopharmacology 98, 163–168CrossRefGoogle Scholar
Ansseau, Mvon Frenckell, RPapart, PMertens, CDe Wilde, JBotte, LDevoitille, JMEvrard, JLDe Nayer, AKoch-Bourdouxhe, SDarimont, PLecoq, AMirel, JCouzinier, JPDemarez, JPSerre, C (1989b) Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 4, 221–227CrossRefGoogle Scholar
Charney, DSHeninger, GR (1986) Abnormal regulation of noradrenergic function in panic disorders. Arch Gen Psychiatry 43, 1042–1054CrossRefGoogle ScholarPubMed
Cottraux, JBouvard, MLegeron, Ρ (1985) Méthodes d’évaluation des comportements. Editions d'Applications Psychotechniques, Issy-les-MoulineauxGoogle Scholar
Hamilton, M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32, 50–55CrossRefGoogle ScholarPubMed
Lipman, RS (1982) Differentiating anxiety and depression in anxiety disorders : use of rating scales. Psychopharmacol Bull 18, 4, 69–77Google ScholarPubMed
Moret, CCharveron, MFinberg, JPMCouzinier, JPBriley, M (1985) Biochemical profile of midalcipran (F2207), l-phenyl-l-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z), hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24, 1211–1219CrossRefGoogle Scholar
Uhde, TWRoy-Byrne, PPVittone, BJBoulenger, JPPost, RM (1985) Phenomenology and neurobiology of panic disorder.In: Anxiety and the Anxiety Disorders (Tuma, AMMaser, JD eds) Lawrence Erlbaum Associates Inc, Hillsdale, NJ, 557–576Google Scholar
Submit a response

Comments

No Comments have been published for this article.